Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 8
2012 12
2013 13
2014 17
2015 10
2016 10
2017 11
2018 16
2019 14
2020 21
2021 20
2022 20
2023 15
2024 31
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases.
Zimmermann M, Fandrich M, Jakobi M, Röben B, Wurster I, Lerche S, Schulte C, Zimmermann S, Deuschle C, Schneiderhan-Marra N, Joos TO, Gasser T, Brockmann K. Zimmermann M, et al. Among authors: brockmann k. NPJ Parkinsons Dis. 2025 Jun 13;11(1):166. doi: 10.1038/s41531-025-00984-3. NPJ Parkinsons Dis. 2025. PMID: 40514404 Free PMC article.
Impact of lifestyle factors on quantitative motor and cognitive performance: insights from a longitudinal study on healthy ageing.
Zimmermann M, Sünkel U, Wurster I, Lerche S, Hobert MA, Schulte C, von Thaler AK, Berg D, Maetzler W, Fallgatter A, Eschweiler GW, Gasser T, Brockmann K, Roeben B. Zimmermann M, et al. Among authors: brockmann k. Geroscience. 2025 Jun 12. doi: 10.1007/s11357-025-01731-5. Online ahead of print. Geroscience. 2025. PMID: 40504353
Neuronal α-Synuclein Disease Stage Progression over 5 Years.
Simuni T, Gochanour C, Nair AR, Brumm MC, Coffey C, Poston KL, Chahine LM, Weintraub D, Tanner CM, Gonzalez-Latapi P, Kopil CM, Xiao Y, Chowdhury S, Dam T, Pagano G, Stephenson D, Siderowf A, Dunn B, Marek K; NSD Working Group the Parkinson's Progression Markers Initiative. Simuni T, et al. Mov Disord. 2025 Apr 30. doi: 10.1002/mds.30191. Online ahead of print. Mov Disord. 2025. PMID: 40302527
High Agreement Across Laboratories Between Different Alpha-Synuclein Seed Amplification Protocols.
Bräuer S, Weber M, Deuschle C, Julia K, Concha-Marambio L, Bernhardt AM, Kadam V, Mengel D, Ruf WP, Kassubek J, Schniewind I, Kuhs S, Rossi M, Parchi P, Levin J, Danzer KM, Synofzik M, Brockmann K, Falkenburger BH. Bräuer S, et al. Among authors: brockmann k. Eur J Neurol. 2025 Apr;32(4):e70165. doi: 10.1111/ene.70165. Eur J Neurol. 2025. PMID: 40237217 Free PMC article.
LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization.
Chahine LM, Lafontant DE, Choi SH, Iwaki H, Blauwendraat C, Singleton AB, Brumm MC, Alcalay RN, Merchant K, Nudelman KNH, Dagher A, Vo A, Tao Q, Venuto CS, Kieburtz K, Poston KL, Bressman S, Gonzalez-Latapi P, Avants B, Coffey C, Jennings D, Tolosa E, Siderowf A, Marek K, Simuni T; Parkinson’s Progression Markers Initiative. Chahine LM, et al. Brain Commun. 2025 Mar 6;7(2):fcaf103. doi: 10.1093/braincomms/fcaf103. eCollection 2025. Brain Commun. 2025. PMID: 40114783 Free PMC article.
Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson's disease.
Tan MM, Iwaki H, Bandres-Ciga S, Sosero Y, Shoai M, Brockmann K, Williams NM, Alcalay RN, Maple-Grødem J, Alves G, Tysnes OB, Auinger P, Eberly S, Heutink P, Simon DK, Kieburtz K, Hardy J, Williams-Gray CH, Grosset DG, Corvol JC, Gan-Or Z, Toft M, Pihlstrøm L. Tan MM, et al. Among authors: brockmann k. medRxiv [Preprint]. 2025 Feb 3:2025.01.31.25321395. doi: 10.1101/2025.01.31.25321395. medRxiv. 2025. PMID: 39974079 Free PMC article. Preprint.
Predictive potential of circular walking in prodromal Parkinson's disease.
Micó-Amigo ME, Kingma I, Heinzel S, Solbrig S, Hobert MA, Elshehabi M, Brockmann K, Metzger FG, van Lummel RC, Berg D, Maetzler W, van Dieën JH. Micó-Amigo ME, et al. Among authors: brockmann k. J Parkinsons Dis. 2025 Feb;15(1):140-153. doi: 10.1177/1877718X241306141. Epub 2025 Jan 14. J Parkinsons Dis. 2025. PMID: 39973512 Free article.
A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy.
Porsche S, Klietz M, Greten S, Piot IA, Jensen I, Wegner F, Ye L, Krey L, Höllerhage M, Pötter-Nerger M, Zeitzschel M, Hagena K, Kassubek J, Süß P, Winkler J, Berg D, Paschen S, Tönges L, Gruber D, Gandor F, Jost WH, Kühn AA, Claus I, Warnecke T, Pedrosa DJ, Eggers C, Trenkwalder C, Classen J, Schwarz J, Schnitzler A, Krause P, Schneider A, Brandt M, Falkenburger B, Zerr I, Bähr M, Weidinger E, Levin J, Katzdobler S, Düzel E, Glanz W, Teipel S, Kilimann I, Prudlo J, Gasser T, Brockmann K, Spottke A, Esser A, Petzold GC, Respondek G, Höglinger GU. Porsche S, et al. Among authors: brockmann k. Mov Disord Clin Pract. 2025 Jan 27. doi: 10.1002/mdc3.14348. Online ahead of print. Mov Disord Clin Pract. 2025. PMID: 39868903
212 results